UBS Group’s Albany Molecular Research Inc AMRI Stock Holding History

UBS Group’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,100	Closed	-$46K	–	8311
2017 Q2	$46K	Buy	2,100 +1,926	+1,107%	+$35K	﹤0.01%	5725
2017 Q1	$2K	Sell	174 -621	-78%	-$10.2K	﹤0.01%	7362
2016 Q4	$14K	Buy	795 +24	+3%	+$408	﹤0.01%	6747
2016 Q3	$13K	Sell	771 -815	-51%	-$12.1K	﹤0.01%	6633
2016 Q2	$22K	Sell	1,586 -289	-15%	-$4.22K	﹤0.01%	6249
2016 Q1	$28K	Sell	1,875 -1,203	-39%	-$18.9K	﹤0.01%	5959
2015 Q4	$61K	Buy	3,078 +2,011	+188%	+$38.2K	﹤0.01%	5653
2015 Q3	$19K	Sell	1,067 -906	-46%	-$18.4K	﹤0.01%	6775
2015 Q2	$40K	Buy	1,973 +1,173	+147%	+$22.6K	﹤0.01%	6207
2015 Q1	$14K	Buy	800 +394	+97%	+$6.71K	﹤0.01%	7389
2014 Q4	$7K	Buy	+406	New	+$7.45K	﹤0.01%	8754

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

UBS Group's AMRI Position: Q3 2017 in Review

UBS Group sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 2,100 shares — an estimated $46K sold.

UBS Group first reported a position in AMRI in Q4 2014 and held it in 11 quarters. The position peaked at $61K in Q4 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

UBS Group reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
UBS Group sold 2,100 Albany Molecular Research Inc shares in Q3 2017, an estimated $46K.
UBS Group first reported a position in Albany Molecular Research Inc in Q4 2014 and held it in 11 quarters.
UBS Group's Albany Molecular Research Inc position peaked at $61K in Q4 2015.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on UBS Group's 13F filing for Q3 2017, filed 14 Nov 2017.